Before our study, another work reported that CHIP mutations in TET2 and DNMT3A occur frequently in patients with CAVD and that CHIP presence at the valve replacement time determines a poor prognosis after successful TAVI11. Here, TET2 is linked to congenital bilateral aplasia of vas deferens from CFTR mutation.